Cambridge Investment Research Advisors
ICPT

Cambridge Investment Research Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,310
Closed -$658K – 2513
2019
Q4 		$658K Buy
+5,310
New +$475K 0.01% 1403

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Cambridge Investment Research Advisors's ICPT Position: Q1 2020 in Review

Cambridge Investment Research Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 5,310 shares — an estimated $658K sold.

Cambridge Investment Research Advisors first reported a position in ICPT in Q4 2019 and held it in 1 quarter. The position peaked at $658K in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

  • Cambridge Investment Research Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 5,310 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $658K.
  • Cambridge Investment Research Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Intercept Pharmaceuticals, Inc. position peaked at $658K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2020, filed 8 May 2020.